DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) --

康涅狄格州丹伯里和加利福尼亚州韦斯特莱克村，2026年7月24日（环球新闻社）--

MannKind Corporation (Nasdaq: MNKD)

曼恩金德公司（纳斯达克股票代码：MNKD）

, a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors.

，一家致力于通过针对心脏代谢疾病和罕见肺病的创新、以患者为中心的解决方案来改变慢性病护理的生物制药公司，今日宣布已与某些机构投资者就私募配售事宜签订证券购买协议。

The gross proceeds from the private placement financing are expected to be approximately $50 million. The closing of the financing is expected to occur on or about July 24, 2026, subject to the satisfaction of customary closing conditions..

本次私募融资的总收益预计约为5,000万美元。在满足惯常交割条件的前提下，预计融资交割将于2026年7月24日或前后完成。

The private placement was led by Frazier Life Sciences, a longstanding biotech investment firm.

本次私募由老牌生物技术投资公司Frazier Life Sciences领投。

MannKind intends to use the net proceeds for general corporate purposes, including funding the $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow™.

MannKind 计划将净收益用于一般企业用途，包括为近期美国食品药品监督管理局（FDA）批准 Furoscix ReadyFlow™ 所触发的 4,500 万美元或有价值权支付提供资金。

Pursuant to the terms of the securities purchase agreement, MannKind is selling an aggregate of 10,440,838 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 2,412,632 shares of its common stock, at a purchase price of $3.89 per share and $3.88 per pre-funded warrant.

根据证券购买协议的条款，MannKind 正在出售总计 10,440,838 股其普通股，并向某些投资者发行预融资权证以替代普通股，该等权证最多可购买总计 2,412,632 股其普通股，每股普通股的购买价格为 3.89 美元，每份预融资权证的购买价格为 3.88 美元。

The pre-funded warrants will have an exercise price of $0.01 per share and will be exercisable at any time after original issuance, subject to certain beneficial ownership limitations, and will not expire until exercised in full..

预融资认股权证的行权价格为每股0.01美元，在初始发行后的任何时间均可行权，但须遵守某些实益所有权限制，且在全部行权前不会到期。

The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and are being issued and sold in reliance on Section 4(a)(2) of the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

本次私募发行和出售的证券未根据经修订的《1933年证券法》或适用的州证券法进行注册，而是依据《证券法》第4(a)(2)条的规定进行发行和出售。除非依据有效的注册声明或适用《证券法》注册要求的豁免规定，否则不得在美国境内要约或出售该等证券。

MannKind has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the pre-funded warrants..

MannKind 已同意向美国证券交易委员会提交注册声明，以登记私下配售中发行的普通股股份以及行使预融资权证时可发行的普通股股份的转售。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售任何此处所述证券的要约，也不构成购买此类证券的要约的招揽；在任何州或司法管辖区，若在此类州或司法管辖区的证券法下完成注册或资格认定前，此类要约、招揽或销售行为属违法，则不得在该等州或司法管辖区进行上述证券的销售。

About MannKind

关于曼金德

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease..

MannKind Corporation（纳斯达克股票代码：MNKD）是一家生物制药公司，致力于通过以患者为中心的创新解决方案改变慢性病护理。我们专注于心脏代谢疾病和罕见肺部疾病，开发和商业化治疗严重未满足医疗需求的产品，包括糖尿病、肺动脉高压以及心力衰竭和慢性肾病中的液体过载问题。

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

凭借在药械组合产品领域的深厚专业知识，MannKind 旨在提供能够无缝融入日常生活的治疗方案。

Learn more at mannkindcorp.com.

更多信息请访问 mannkindcorp.com。

Forward Looking Statements

前瞻性陈述

Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the satisfaction of closing conditions for a private placement and the payment to holders of contingent value rights associated with a regulatory milestone.

本新闻稿中非历史事实的陈述均为前瞻性陈述，涉及风险和不确定性。这些陈述包括但不限于有关满足私募交割条件以及支付与监管里程碑相关的或有价值权持有人款项的陈述。

Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that MannKind’s products may only achieve a limited degree of commercial success, and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K.

“相信”、“预计”、“计划”、“预期”、“打算”、“将”、“目标”、“潜力”等词语及类似表述旨在识别前瞻性陈述。这些前瞻性陈述基于 MannKind 当前的预期。由于各种风险和不确定性，实际结果和事件发生的时间可能与上述前瞻性陈述中的预期存在重大差异，包括但不限于 MannKind 的产品仅能取得有限商业成功的风险，以及 MannKind 向美国证券交易委员会（SEC）提交的文件中详述的其他风险，包括其截至 2025 年 12 月 31 日止年度的 10-K 表年度报告，以及后续的 10-Q 表定期报告和 8-K 表当前报告。

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release..

谨提醒您，切勿过度依赖这些前瞻性陈述，其仅反映本新闻稿发布之日的情况。本警示性声明对所有前瞻性陈述均具有全面的限定效力，且 MannKind 公司不承担修订或更新任何前瞻性陈述以反映本新闻稿发布日期之后发生的事件或情况的义务。

FUROSCIX READYFLOW and MANNKIND are trademarks of MannKind Corporation.

FUROSCIX READYFLOW 和 MANNKIND 是 MannKind 公司的商标。